Do Fibroids Look Different Than Cancer on Ultrasound?

Fibroids and uterine cancers do look different on ultrasound in many cases, but the differences are not always clear-cut. A typical fibroid appears as a well-defined, round mass with characteristic shadowing, while a uterine sarcoma tends to show irregular borders and heavy internal blood flow. The problem is that fibroids are extraordinarily common and sarcomas are rare, and the two can share enough overlapping features to make confident diagnosis on ultrasound alone genuinely difficult. A pooled analysis of the available research found that ultrasound has only moderate accuracy for telling the two apart, with sensitivity around 76% and specificity around 89%.¹

What Fibroids Look Like on a Standard Ultrasound

Fibroids, also called leiomyomas, have a fairly recognizable ultrasound appearance most of the time. They show up as well-defined, solid, round masses sitting inside the muscular wall of the uterus or bulging from it.² Their brightness on the screen (echogenicity) is usually close to the surrounding uterine muscle, though they can appear darker. One hallmark feature is acoustic shadowing, a dark band behind the fibroid created by the sound waves hitting the dense, organized tissue. That shadowing can appear at the edges of the fibroid or fan out from internal structures, and it arises from the interface between the fibroid’s smooth-muscle whorls, its connective tissue, and the normal uterine wall around it.³⁴

Blood flow in a fibroid tends to wrap around the outside. That circumferential pattern is a reflection of the pseudocapsule, a thin shell of compressed tissue and vessels that forms around the growing mass. These features together give fibroids a tidy, contained look that experienced sonographers learn to recognize quickly. Most fibroids are also described as having symmetry and distinct edges, which contrasts with how many malignant lesions present.⁵

What Uterine Sarcomas Look Like on Ultrasound

Uterine sarcomas are the cancers most often confused with fibroids, since both grow from the muscular wall of the uterus. On ultrasound, sarcomas tend to look messier. In a study that compared the two using standardized descriptive terms, about 69–81% of sarcomas had irregular borders, while 71–90% of fibroids had regular, smooth borders.⁶ That border irregularity is one of the strongest visual clues. Sarcomas also showed a non-uniform internal texture in nearly all cases (94%), compared with about half to three-quarters of fibroids. Calcifications, which sometimes appear in older fibroids, were essentially absent in sarcomas.

The most striking difference involves blood flow. Sarcomas are richly vascularized tumors. In the same study, roughly 81–94% of sarcomas had moderate-to-abundant blood flow inside the mass, fed by vessels that grow chaotically through the tumor rather than neatly encircling it.⁶ Rapid growth is another red flag that clinicians watch for alongside the imaging findings.⁷

Why the Overlap Makes Things Harder Than It Sounds

Reading a list of distinguishing features might make it seem like telling fibroids from sarcomas should be straightforward. In practice, it is not. Imaging experts have long acknowledged that the two can have overlapping appearances, and no single ultrasound feature reliably separates them.⁸ A large fibroid that has undergone degeneration (where parts of it lose blood supply and break down internally) can develop irregular internal textures, heavy blood flow, and even cystic areas that mimic what you would expect in a malignancy.⁹ Conversely, a small or early sarcoma can look deceptively round and well-bordered.

The numbers bear this out. That same pooled analysis found that while ultrasound correctly identifies about 89% of true fibroids (specificity), it only catches about 76% of sarcomas (sensitivity). That gap means roughly one in four sarcomas could be missed or mistaken for a fibroid on a standard scan.¹ Given that sarcomas are already rare, this becomes a needle-in-a-haystack problem compounded by imperfect imaging.

What Doppler Blood-Flow Measurement Adds, and Where It Falls Short

Color Doppler ultrasound shows blood flow in real time, which is why many clinicians use it to assess how vascularized a uterine mass is. The idea is intuitive: cancers need heavy blood supply, so masses with a lot of internal flow should raise suspicion. Visually, this works reasonably well. Seeing abundant, chaotic flow inside a mass does prompt more concern than seeing flow that stays neatly at the periphery.

Where Doppler gets less useful is in the quantitative measurements it generates. One common metric is the resistance index, a number that reflects how much resistance blood encounters flowing through a vessel. In theory, the abnormal vessels in tumors should have lower resistance. But an early study found no meaningful difference in resistance index between fibroids and sarcomas.¹⁰ A later study found a significant difference between fibroids and one subtype of uterine cancer (malignant mixed mesodermal tumors) but not between fibroids and leiomyosarcomas specifically.¹¹ The takeaway is that Doppler helps paint the overall picture, especially as a visual tool, but a single number from it is not going to make the diagnosis.

Contrast-Enhanced Ultrasound and Its Promise

A newer approach uses contrast-enhanced ultrasound, where tiny gas-filled microbubbles are injected into the bloodstream and then tracked as they flow through the uterine mass. This technique reveals the vascular architecture in much finer detail than standard Doppler can manage. In fibroids, the contrast tends to light up the pseudocapsule first, then fill inward in an orderly pattern. Most fibroids also wash out the contrast faster than the surrounding uterine muscle.¹²

Sarcomas behave differently. They show heterogeneous, intensely bright enhancement due to their heavy blood supply, and their borders remain poorly defined even with contrast. In one comparison, contrast-enhanced ultrasound caught all nine sarcomas in a group that included fibroids showing signs of degeneration, while conventional ultrasound caught only two of those same sarcomas.¹² That is a meaningful improvement, though the numbers are small and the technique is not universally available.

When Adenomyosis Muddies the Picture

Fibroids are not the only benign condition that needs to be distinguished from cancer. Adenomyosis, where tissue from the uterine lining grows into the muscular wall, can create confusing ultrasound images as well. Fibroids push surrounding muscle aside as they grow, staying compact and round with clear borders. Adenomyosis infiltrates the muscle, producing ill-defined areas of mixed brightness with small internal cysts.¹³ For a reader wondering about cancer, the concern is that an adenomyotic area can look irregular and alarming in the same way a sarcoma does.

Separating adenomyosis from fibroids matters for treatment decisions, not just cancer screening. Fibroids can be surgically removed with a myomectomy and the surrounding muscle recovers. Adenomyosis infiltrates the muscle itself, so surgery carries a risk of losing healthy tissue. In one study, about 15% of patients initially suspected of having adenomyosis on ultrasound turned out to have something else entirely, most often small fibroids that had been misread.¹⁴ Elastography, a technique that measures tissue stiffness, has shown some ability to separate these conditions. Fibroids are stiffer than normal uterine muscle, while adenomyosis is softer, and the measured stiffness ratios were significantly different between the two groups and a control group.¹⁵

Does Operator Experience Matter?

You might assume that a more experienced radiologist or sonographer would be better at catching subtle signs of cancer. Surprisingly, at least one study that tested this directly found that reader experience did not affect diagnostic accuracy when distinguishing fibroids from sarcomas on ultrasound.¹⁶ This suggests the limitation is more about what ultrasound can physically show than about how well the person reading it interprets the images. Soft-tissue contrast on ultrasound is inherently limited compared with MRI, which is one reason MRI is often the next step when a mass looks suspicious.

There has been an effort to standardize how ultrasound operators describe what they see. The MUSA (Morphological Uterus Sonographic Assessment) framework provides a shared vocabulary for describing borders, echogenicity, shadows, vascularity, and other features of uterine masses.¹⁷ The goal is to reduce the subjectivity of ultrasound reporting. If every clinician uses the same terms for the same features, it becomes easier to pool data, build scoring systems, and eventually create reliable algorithms for flagging suspicious masses.

Structured Scoring Systems and AI Approaches

Building on standardized descriptions, researchers have developed clinical algorithms that combine ultrasound features into a score. One such system achieved 98% sensitivity for identifying sarcomas, meaning it caught nearly all the cancers in the study. The tradeoff was specificity of about 58%, meaning it flagged a lot of benign lesions for further investigation too.¹⁸ For a cancer screening tool, this is a defensible balance. You would rather over-investigate some fibroids than miss a sarcoma.

Machine learning is also being tested on this problem. One pilot used clinical data combined with ultrasound assessments of 68 patients and found that the two most important features for the algorithm were tumor borders and lesion consistency, which aligns with what experienced clinicians already watch for. Its best performance was very high, though the sample was small.¹⁹ A separate study used radiomics, where software extracts hundreds of quantitative features from ultrasound images that the human eye cannot perceive. The best classifier in that study reached about 85% accuracy with 80% sensitivity.²⁰ These tools are still in development and not ready for routine clinical use, but they point toward a future where the inherent limitations of human visual interpretation may be partially overcome.

When and Why MRI Gets Ordered

If your ultrasound shows a mass that does not clearly look like a typical fibroid, the usual next step is an MRI. This is because MRI has much better soft-tissue discrimination than ultrasound does. A fibroid with the classic MRI appearance (a low-signal, whorled mass on T2-weighted images) has a very high negative predictive value for being benign, meaning that if it looks like a standard fibroid on MRI, it almost certainly is one.²¹ Sarcomas, by contrast, tend to show bright signal on T2 images, areas of necrosis, and uneven contrast uptake that make them more distinguishable from fibroids on MRI than they are on ultrasound.

That said, MRI is not perfect either, and some overlap persists. Degenerating fibroids can show bright T2 signal and areas that mimic necrosis, which is why even MRI sometimes leads to uncertainty. The definitive answer often comes only after the mass has been removed and examined under a microscope. This is one reason clinicians weigh all available information together: the imaging appearance, the speed of growth, the patient’s symptoms, menopausal status, and blood markers when available.

Fibroid Degeneration and Its Many Disguises

Fibroids are not static. Over time, especially as they grow large, their internal blood supply can become insufficient, leading to different types of degeneration. Hyaline degeneration (the most common) replaces smooth muscle with a glassy connective tissue. Cystic degeneration creates fluid-filled spaces. Red or carneous degeneration happens when the blood supply is suddenly cut off, often during pregnancy. Each of these changes the ultrasound appearance in ways that can make a previously clear-looking fibroid suddenly appear ambiguous.

Cystic degeneration is particularly tricky. When a fibroid develops large internal cysts, it can be confused on imaging not only with a sarcoma but even with an ovarian cystic malignancy. One case report described a pelvic cystic mass with a solid component that was initially considered malignant but turned out to be a degenerating fibroid.⁹ For patients who have been told they have fibroids and are undergoing surveillance with periodic ultrasounds, a change in the appearance of a previously stable fibroid does not automatically mean cancer. Degeneration is far more common than malignant transformation and is a normal part of fibroid biology. Still, a significant change in appearance is reason to have it evaluated more closely.

How Rare Is Cancer Actually Being Found?

Context matters enormously here. Uterine fibroids are present in a large proportion of women of reproductive age, while uterine sarcomas account for a tiny fraction of uterine tumors. Most estimates put the prevalence of unexpected sarcoma at well under 1% in patients undergoing surgery for presumed fibroids. The practical implication is that the overwhelming majority of masses that look like fibroids on ultrasound are fibroids. When sonographers and radiologists describe an ultrasound finding as “consistent with fibroids,” they are right the vast majority of the time.

The flip side is that the very rarity of sarcomas makes them easy to miss. Because almost every uterine mass is benign, there is a natural tendency to assume benignity. The clinical algorithms and machine-learning tools discussed above are partly an attempt to counteract that: to create systematic triggers that flag the handful of cases where further workup is warranted, rather than relying on a clinician’s subjective gut feeling about whether a mass “looks funny.”

Practical Situations That Raise the Index of Suspicion

Certain clinical scenarios push clinicians toward more aggressive investigation even when the ultrasound looks ambiguous rather than clearly malignant. These include:

Postmenopausal growth: Fibroids generally shrink after menopause because they are sensitive to estrogen and progesterone. A uterine mass that is growing in a postmenopausal woman who is not on hormone therapy is treated with higher suspicion.
Rapid size increase: While “rapid growth” used to be considered a hallmark of sarcoma, recent thinking has tempered this somewhat. Many fibroids grow quickly and most turn out benign. Still, very fast growth combined with other unusual features gets attention.
Unusual Doppler patterns: Heavy, disorganized internal vascularity rather than the neat circumferential pattern expected in fibroids.
Solitary, large, soft masses: A single large mass with irregular texture is more concerning than multiple well-defined fibroids of various sizes, which is the typical pattern of benign fibroid disease.

None of these features alone confirms malignancy. They function as pieces of a puzzle. When several are present simultaneously, clinicians are more likely to order MRI, biopsy if feasible, or recommend surgery with careful pathological examination rather than a watch-and-wait approach.

What Patients Can Expect During Follow-Up Imaging

If you have been diagnosed with fibroids and are monitoring them with periodic ultrasounds, your sonographer is looking for changes over time rather than making a diagnosis from scratch at each visit. Stability is reassuring. A fibroid that looks the same from one year to the next is very unlikely to be malignant. The features that prompt concern are the ones that change: a smooth border becoming irregular, a mass that was relatively uniform internally developing areas of mixed or complex appearance, or a previously stable mass that has grown substantially between scans.

Understanding this can reduce some of the anxiety that comes with repeat imaging. A sonographer spending extra time on a particular mass or switching to Doppler to check blood flow does not mean they have found something bad. These are standard parts of a thorough exam. If anything does look concerning, the next step is usually an MRI, not immediate surgery. The pathway from “this looks a little unusual on ultrasound” to “this might be cancer” involves multiple checkpoints, and most masses that raise mild concern on ultrasound turn out to be degenerating fibroids or other benign variants when investigated further.

1
PubMed. Diagnostic Accuracy of Ultrasound in the Diagnosis of Uterine Leiomyomas and Sarcomas
2
Journal of Medical Ultrasound. Ultrasonography of Uterine Leiomyomas
3
Glob Libr Women’s Med. Benign Myometrial Pathology (Fibroids): Ultrasound Features and Practical Tips
4
PubMed. Acoustic shadowing from uterine leiomyomas: sonographic-pathologic correlation
5
PubMed Central. Transvaginal Ultrasound Combined with Strain-Ratio Elastography for the Concomitant Diagnosis of Uterine Fibroids and Adenomyosis: A Pilot Study
6
PubMed. Ultrasound features using MUSA terms and definitions in uterine sarcoma and leiomyoma: cohort study
7
PubMed Central. Uterine Myomas and Sarcomas – Clinical and Ultrasound Characteristics and Differential Diagnosis Using Pulsed and Color Doppler Techniques
8
Diagnostic and Interventional Imaging. How to differentiate uterine leiomyosarcoma from leiomyoma with imaging
9
PubMed Central. Diagnostic Challenge: Distinguishing Uterine Fibroid with Cystic Degeneration vs. Ovarian Cystic Malignancy. A Case Report
10
PubMed. Uterine sarcoma: can it be differentiated from uterine leiomyoma with Doppler ultrasonography? A preliminary report
11
PubMed. Uterine sarcomas versus leiomyomas: gray-scale and Doppler sonographic findings
12
PubMed Central. Contrast-Enhanced Ultrasound Imaging of Uterine Disorders: A Systematic Review
13
Glob Libr Women’s Med. Endometriosis and Adenomyosis: Ultrasound Features and Diagnosis
14
PubMed. Adenomyosis: sonographic findings and diagnostic accuracy
15
PubMed. Importance of Transvaginal Elastography in the Diagnosis of Uterine Fibroids and Adenomyosis
16
Academic Radiology. Diagnostic Accuracy of Ultrasound, Contrast-enhanced CT, and Conventional MRI for Differentiating Leiomyoma From Leiomyosarcoma
17
PubMed. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group
18
American Journal of Obstetrics and Gynecology. A clinical ultrasound algorithm to identify uterine sarcoma and smooth muscle tumors of uncertain malignant potential in patients with myometrial lesions
19
Artificial Intelligence in Medicine. A human-interpretable machine learning pipeline based on ultrasound to support leiomyosarcoma diagnosis
20
Gynecologic Oncology. Using rADioMIcs and machine learning with ultrasonography for the differential diagnosis of myometRiAL tumors (the ADMIRAL pilot study)
21
PubMed Central. Differentiating uterine sarcoma from leiomyoma: BET1T2ER check!